MX2024002857A - Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. - Google Patents

Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.

Info

Publication number
MX2024002857A
MX2024002857A MX2024002857A MX2024002857A MX2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A
Authority
MX
Mexico
Prior art keywords
milvexian
prevention
treatment
thromboembolic disorders
thromboembolic
Prior art date
Application number
MX2024002857A
Other languages
English (en)
Spanish (es)
Inventor
Dietmar Alfred Seiffert
Gary Peters
Joseph M Luettgen
John Strony
Madhu Chintala
Christopher Nessel
Liyanage Vidya Perera
Danshi Li
Charlotte Jones-Burton
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2024002857A publication Critical patent/MX2024002857A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002857A 2021-09-17 2022-09-16 Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. MX2024002857A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US202163278582P 2021-11-12 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
MX2024002857A true MX2024002857A (es) 2024-03-21

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002857A MX2024002857A (es) 2021-09-17 2022-09-16 Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.

Country Status (11)

Country Link
US (1) US20250099466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401736A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534427A (cg-RX-API-DMAC7.html)
KR (1) KR20240060820A (cg-RX-API-DMAC7.html)
AU (1) AU2022345862A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232633A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000776A1 (cg-RX-API-DMAC7.html)
IL (1) IL310894A (cg-RX-API-DMAC7.html)
MX (1) MX2024002857A (cg-RX-API-DMAC7.html)
TW (1) TW202327607A (cg-RX-API-DMAC7.html)
WO (1) WO2023043999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565231A1 (en) * 2022-08-01 2025-06-11 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
CN121001727A (zh) * 2023-04-19 2025-11-21 百时美施贵宝公司 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途
CN121443289A (zh) * 2023-04-19 2026-01-30 百时美施贵宝公司 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途
CN121398811A (zh) * 2023-04-19 2026-01-23 百时美施贵宝公司 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2026115567A1 (en) * 2024-11-26 2026-06-04 Dr. Reddy’S Laboratories Limited Sustained release formulations of milvexian

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20210151183A (ko) 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능

Also Published As

Publication number Publication date
US20250099466A1 (en) 2025-03-27
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
TW202327607A (zh) 2023-07-16
CA3232633A1 (en) 2023-03-23
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
WO2023043999A1 (en) 2023-03-23
EP4401736A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
CL2024000776A1 (es) Milvexian para la prevención y el tratamiento de trastornos tromboembólicos
JOP20230190A1 (ar) مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس
CY1122867T1 (el) Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας
MX2022000711A (es) Inhibidores de parp1.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2024000349A (es) Compuestos y usos de los mismos.
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
MX2021012359A (es) Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
CO2019014647A2 (es) Composiciones inmunogénicas
CY1124540T1 (el) Συνθεσεις και μεθοδοι που σχετιζονται με αγωνιστες 5-ht1f πυριδινοϋλοπιπεριδινης
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2021002995A (es) Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.
MX2024006769A (es) Compuestos y usos de los mismos.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
UY40381A (es) Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico